ESR1 and breast carcinoma: While the MASTL transcription factor is currently unknown, MASTL is a potential DREAM target (Fischer et al., 2016) and recent evidence also suggests that MASTL transcription can be increased by E2F8 in ER positive breast cancer cells (Tian et al., 2017).